Compare Fresenius Kabi Onco. with Orchid Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ORCHID PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ORCHID PHARMA 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ORCHID PHARMA FRESENIUS KABI ONCO./
ORCHID PHARMA
 
P/E (TTM) x 22.1 -133.2 - View Chart
P/BV x 3.1 38.2 8.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   ORCHID PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ORCHID PHARMA
Sep-13
FRESENIUS KABI ONCO./
ORCHID PHARMA
5-Yr Chart
Click to enlarge
High Rs176194 90.7%   
Low Rs7935 224.3%   
Sales per share (Unadj.) Rs37.7276.5 13.6%  
Earnings per share (Unadj.) Rs5.1-79.2 -6.4%  
Cash flow per share (Unadj.) Rs6.7-43.5 -15.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.553.9 78.9%  
Shares outstanding (eoy) m158.2370.45 224.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.40.4 815.3%   
Avg P/E ratio x25.0-1.4 -1,728.4%  
P/CF ratio (eoy) x18.9-2.6 -718.3%  
Price / Book Value ratio x3.02.1 140.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1358,067 249.6%   
No. of employees `0001.22.8 41.1%   
Total wages/salary Rs m7032,527 27.8%   
Avg. sales/employee Rs Th5,176.26,956.1 74.4%   
Avg. wages/employee Rs Th610.4902.5 67.6%   
Avg. net profit/employee Rs Th699.6-1,993.0 -35.1%   
INCOME DATA
Net Sales Rs m5,96319,477 30.6%  
Other income Rs m18407 4.4%   
Total revenues Rs m5,98119,884 30.1%   
Gross profit Rs m1,4301,103 129.7%  
Depreciation Rs m2582,519 10.2%   
Interest Rs m-265,227 -0.5%   
Profit before tax Rs m1,216-6,236 -19.5%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68511 -13.3%   
Tax Rs m342-125 -273.3%   
Profit after tax Rs m806-5,580 -14.4%  
Gross profit margin %24.05.7 423.6%  
Effective tax rate %28.12.0 1,401.5%   
Net profit margin %13.5-28.7 -47.2%  
BALANCE SHEET DATA
Current assets Rs m5,10211,014 46.3%   
Current liabilities Rs m2,38532,060 7.4%   
Net working cap to sales %45.6-108.1 -42.2%  
Current ratio x2.10.3 622.5%  
Inventory Days Days15095 158.1%  
Debtors Days Days11334 337.6%  
Net fixed assets Rs m5,14829,440 17.5%   
Share capital Rs m158705 22.5%   
"Free" reserves Rs m6,5562,043 320.9%   
Net worth Rs m6,7323,800 177.2%   
Long term debt Rs m9529,018 10.6%   
Total assets Rs m10,38846,510 22.3%  
Interest coverage x-45.8-0.2 23,703.9%   
Debt to equity ratio x0.12.4 6.0%  
Sales to assets ratio x0.60.4 137.1%   
Return on assets %7.5-0.8 -987.8%  
Return on equity %12.0-146.9 -8.2%  
Return on capital %14.6-3.7 -391.0%  
Exports to sales %74.537.9 196.6%   
Imports to sales %24.822.6 109.5%   
Exports (fob) Rs m4,4417,378 60.2%   
Imports (cif) Rs m1,4774,406 33.5%   
Fx inflow Rs m5,2987,513 70.5%   
Fx outflow Rs m1,7725,649 31.4%   
Net fx Rs m3,5251,865 189.1%   
CASH FLOW
From Operations Rs m1,2741,682 75.8%  
From Investments Rs m-1,204-9,860 12.2%  
From Financial Activity Rs m-1966,644 -3.0%  
Net Cashflow Rs m-126-1,535 8.2%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.6 6.5%  
FIIs % 9.6 3.3 290.9%  
ADR/GDR % 0.0 4.6 -  
Free float % 9.1 55.3 16.5%  
Shareholders   42,599 84,811 50.2%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   FDC  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - DIVIS LABORATORIES COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS